Bhuiyan Asma Akter, Brahmachari Sreyashi, Ripa Israt Jahan, Noor Rashed
Molecular Biotechnology and Bioinformatics, Department of Industrial Biotechnologies, Universita Degli Studi di Milano, 20134 Milan, Italy.
Medical Biotechnology, Department of Pharmaceutical, Veterinary and Medical Biotechnologies, Università di Bologna, 40126 Bologna, Italy.
Bull Natl Res Cent. 2022;46(1):176. doi: 10.1186/s42269-022-00867-0. Epub 2022 Jun 20.
The unpredicted pandemic disease COVID-19 first flared up adversely in Europe by imparting interminable force of infected and fatality cases to Italy. In late February 2020, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in northern Italy and swiftly proliferated to the entire country, albeit continuous to date (23 March 2022) with a lesser extent of deadliness. Current review focused on the invasions and the associated consequences by SARS-CoV-2 during the period of March 2020-March 2022.
Initially, the lethality and transmissibility of the novel virus made Italy stunned within 1 month, the number of death cases reached 12,428 at the end of March 2020. The Italian Government announced an immediate emergency phase in entire country, educational institutions to local businesses, manufacturing works, cultural activities to elective activities were rescinded and all the hospitals to morgues were swamped, ensuing that fear of epidemic was impended. Besides, the Italian National Health System and Service coordinated massive public health interventions and conferred unprecedented efforts to limit the high mortality rate of the first wave of infection. Amidst 2 years of epidemic (as of 23 March 2022), Italy has documented 14,070,450 (23.74% of the population) confirmed infected cases, 12,685,306 (21.41% of the population) healed cases, 158,254 death cases (0.27% of the population) and ranking 9th worldwide in the number of deaths.
Based on publicly available Italian Ministry of Health COVID-19 data, current review has comprehended region-wise total infected cases, death cases and healed cases for three consecutive years 2020-2022 to foresee different patterns of the regional outbreak and gradual subservience. At a glance, we highlighted the overview of the exhaustion and exertion of COVID-19 crisis throughout the periods in Italy.
不可预测的大流行性疾病新冠病毒病首先在欧洲爆发，给意大利带来了大量的感染病例和死亡病例。2020年2月下旬，新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在意大利北部出现，并迅速蔓延至全国，尽管截至2022年3月23日仍在持续，但致死率有所降低。本综述聚焦于2020年3月至2022年3月期间SARS-CoV-2的侵袭情况及相关后果。
最初，这种新型病毒的致死率和传播性在1个月内就让意大利陷入震惊，到2020年3月底死亡病例数达到12428例。意大利政府宣布在全国立即进入紧急状态，从教育机构到当地企业、制造业工厂、文化活动到选举活动都被取消，所有医院到停尸房都人满为患，随之而来的是对疫情的恐惧。此外，意大利国家卫生系统和服务部门协调了大规模的公共卫生干预措施，并付出前所未有的努力来限制第一波感染的高死亡率。在两年的疫情期间（截至2022年3月23日），意大利记录了14070450例确诊感染病例（占人口的23.74%）、12685306例治愈病例（占人口的21.41%）、158254例死亡病例（占人口的0.27%），死亡人数在全球排名第9。
基于意大利卫生部公开的新冠病毒病数据，本综述梳理了2020 - 2022年连续三年各地区的总感染病例、死亡病例和治愈病例，以预测地区疫情爆发的不同模式和逐渐得到控制的情况。概览之下，我们突出了意大利在整个时期新冠病毒病危机的疲惫与努力概况。
